{
    "clinical_study": {
        "@rank": "61934", 
        "arm_group": [
            {
                "arm_group_label": "Stage IA or I/II NSCLC", 
                "arm_group_type": "Experimental", 
                "description": "Resection or radiotherapy without adjuvant chemotherapy followed by 3 cycles of vaccination."
            }, 
            {
                "arm_group_label": "Stage IB/II/IIIA", 
                "arm_group_type": "Experimental", 
                "description": "Resection and adjuvant chemotherapy followed by 3 cycles of vaccination."
            }, 
            {
                "arm_group_label": "Stage IIIA or IIIB", 
                "arm_group_type": "Experimental", 
                "description": "Concomitant chemo-irradiation followed by 3 cycles of vaccination."
            }
        ], 
        "brief_summary": {
            "textblock": "All subjects will receive the vaccine subcutaneously every 3 weeks x 3 and then every 3\n      months for 3 years. The rationale for using Poly-ICLC as an adjuvant are two ongoing trials\n      at University of Pittsburgh Cancer Institute (UPCI) of the MUC1 100mer peptide vaccine - one\n      as a therapeutic vaccine in subjects with metastatic castrate resistant prostate cancer and\n      the other in subjects with advanced colonic adenomas at risk for developing colon cancer.\n      The same formulation, MUC1 100mer peptide admixed with Poly-ICLC, is used in both trials.\n      There has been no toxicity observed and the vaccine is highly immunogenic in early disease.\n      In the proposed NSCLC trial the anti-MUC1 immune response will be thoroughly characterized."
        }, 
        "brief_title": "Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer", 
        "completion_date": {
            "#text": "November 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Non-small Cell Lung Cancer (NSCLC)", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects must have histologically or cytologically confirmed non-small cell lung\n             cancer (NSCLC)\n\n          -  All subjects must have one of the following stages: Stage IA(T1NO); IB (T2NO), II &\n             IIIA (N2 negative); IIIA (N2+), IIIB (N3+)\n\n          -  Patients must have stable disease at the time of enrollment\n\n          -  Women and men at least 18 years of age\n\n          -  ECOG performance status 0-1(Appendix A)\n\n          -  Subjects must be within 4 to 6 weeks of standard of care treatment for their\n             particular stage of disease\n\n          -  Subjects must have acceptable organ and marrow function as defined below:\n\n               -  Leukocytes > 3,000/\u00b5L\n\n               -  Absolute Neutrophils > 1,500/\u00b5L\n\n               -  Hemoglobin > 10 g/dL\n\n               -  Platelets > 100,000/\u00b5L\n\n               -  Total Bilirubin  within normal institutional limits\n\n               -  Creatinine  within normal institutional limits OR\n\n               -  Creatinine clearance > 60 mL/min/1.73 m2 for subjects with above normal AST and\n                  ALT with alkaline phosphatase within < 1.5 times upper limit of normal\n\n          -  The effects of a MUC1vaccine on the developing human fetus at the recommended\n             therapeutic dose are unknown. For this reason, men and women of childbearing\n             potential must be willing to use effective contraception (hormonal barrier method of\n             birth control; abstinence) while on study treatment and for at least 3 months\n             thereafter. Should a woman become pregnant or suspect she is pregnant while\n             participating in this study, she should inform her treating physician immediately\n\n        Exclusion Criteria:\n\n          -  Subjects may not be receiving any other investigational agents\n\n          -  Positive ANA lab result\n\n          -  Known Hepatitis B on immunomodulators  (i.e. interferon)\n\n          -  Known Hepatitis C on immunomodulators (i.e. interferon)\n\n          -  No prior vaccine therapy\n\n          -  Patients may not be receiving any steroids or other anti-immune therapy at the time\n             of registration.\n\n          -  Subjects must not be more than 6 weeks from standard of care treatment for their\n             particular stage of disease\n\n          -  Subjects must not have post-obstructive pneumonia or other serious infection at the\n             time of registration or other serious underlying medical condition that would impair\n             the ability of the subjects to receive protocol treatment\n\n          -  Prior resection of lung cancer is allowed, if at least five years have elapsed\n             between previous resection and registration\n\n          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active\n             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac\n             arrhythmia, or psychiatric illness/social situations that would limit compliance with\n             study requirements\n\n          -  Pregnant women are excluded from this study. Women of childbearing potential must\n             have a negative pregnancy test\n\n          -  Subjects with immune deficiency are not expected to respond to the vaccine.\n             Therefore, known HIV-positive patients are excluded from the study\n\n          -  Subjects with a history of known autoimmune disease are excluded from this study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 31, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01720836", 
            "org_study_id": "11-094", 
            "secondary_id": "902168"
        }, 
        "intervention": {
            "arm_group_label": [
                "Stage IA or I/II NSCLC", 
                "Stage IB/II/IIIA", 
                "Stage IIIA or IIIB"
            ], 
            "description": "The vaccine will consist of 100 micrograms of MUC1 100mer peptide dissolved in 50 micro-liters of sterile saline, admixed with 500 micrograms of Hiltonol\u00ae in 250 microliters volume, for a total injection volume of 300 microliters.", 
            "intervention_name": "Vaccine + PolyICLC", 
            "intervention_type": "Biological"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Carboxymethylcellulose Sodium", 
                "Poly I-C", 
                "Poly ICLC"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "December 2, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Pittsburgh", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "15232"
                }, 
                "name": "UPMC Hillman Cancer Center"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "Study of the Immunogenicity of the MUC1 Peptide - Poly-ICLC (Polyinosinic-polycytidylic Acid Stabilized With Polylysine and Carboxymethylcellulose) OR HILTONOL\u2122 Adjuvant Vaccine in Patients With Localized and Locally Advanced Non-Small Cell Lung Cancer", 
        "overall_contact": {
            "email": "wardj@upmc.edu", 
            "last_name": "Julie Ward, RN, BSN", 
            "phone": "412-647-8583"
        }, 
        "overall_contact_backup": {
            "email": "forsterje@upmc.edu", 
            "last_name": "Judy Forster, RN, BSN, BS", 
            "phone": "412-647-8579"
        }, 
        "overall_official": {
            "affiliation": "University of Pittsburgh", 
            "last_name": "David Odell, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "November 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Immunologic response will be measured by increases in anti MUC1 antibody titers post vaccination at different stages of disease: localized (Stage I, II) or locally advanced (Stage III) non-small cell lung cancer.", 
            "measure": "Immunologic response", 
            "safety_issue": "No", 
            "time_frame": "3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01720836"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Pittsburgh", 
            "investigator_full_name": "Olivera Finn", 
            "investigator_title": "Professor of Immunology", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "To assess spontaneous anti- MUC1 immunity in response to cancer prior to administration of the MUC1 vaccine", 
                "measure": "anti-MUC1 immunity", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "description": "To assess the association between baseline MUC1 immunity and vaccine - induced increases in anti MUC1 antibodies", 
                "measure": "Association between baseline MUC1 immunity and vaccine", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "description": "To characterize the change in the balance between immunocompetence (response of T cells to polyclonal stimulation) versus immunosuppression at different stages of disease {check for increased numbers of regulatory T cells (Treg) and Myeloid-Derived Suppressor Cells (MDSC)}", 
                "measure": "Immunocompetence versus immunosuppression", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "description": "To monitor adverse events associated with the study agents", 
                "measure": "MUC1 associated safety", 
                "safety_issue": "Yes", 
                "time_frame": "3 years"
            }, 
            {
                "description": "To evaluate the association between the anti-MUC1 response (preexistent and/or induced or boosted by the vaccine) and recurrence or progression of lung cancer", 
                "measure": "anti-MUC1 response association with recurrence or progression", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }
        ], 
        "source": "University of Pittsburgh", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Olivera Finn", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}